BioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line Guidance

VOXZOGO™ $34 Million Contribution Drives Total Revenues of $534 Million in the Quarter; Total Revenues Grew 13% Year-Over-Year, Excluding Kuvan BioMarin...

Related Keywords

Australia ,Japan ,United States ,Canada ,Debra Charlesworth ,Biomarin Aldurazyme ,Traci Mccarty ,Jean Jacques Bienaim ,Endocrine Society Annual Meeting ,International Society On Thrombosis ,Biomarin Pharmaceutical Inc ,Nasdaq ,Replay International Number ,Company Annual Report On Form ,Biomarin Genzyme ,Committee For Medicinal Products Human Use ,Drug Administration ,European Commission ,Development Expense ,Exchange Commission ,International Number ,European Medicines Agency ,Development Portfolio ,Contribution Drives Total Revenues ,Total Revenues Grew ,Marin Expects ,Severe Hemophilia ,Will Be Approved ,Third Quarter ,Biologics License Application ,Product Revenues Marketed ,Generally Accepted Accounting Principles ,Biomarin Pharmaceutical ,Chief Executive Officer ,Total Revenues ,Product Launches ,Anticipated Approvals ,Society Annual Meeting ,Medicinal Products ,Human Use ,International Society ,Product Life Cycle Expansion Opportunities ,Hereditary Angioedema ,Duchenne Muscular Dystrophy ,Investigational New Drug ,Year Financial Guidance ,Financial Guidance ,Canada Dial In Number ,Dial In Number ,International Dial In Number ,Net Product Revenues ,Administrative Expense ,Quarterly Report ,Nonqualified Deferred Compensation ,Consolidated Financial Statements ,Annual Report ,Months Ended June ,Asset Amortization ,Contingent Consideration ,Intangible Asset ,From Income Taxes ,Guidance Year Ending December ,Marin Pharmaceutical ,